Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

View Full Paper
Ask AI
Bookmark
Share

Authors

SASameem AbedinVBVictor BaidooRJRichard J. Jones

Discussion

Loading...

Member takes

Overview

Post hoc analysis shows maintenance therapy does not improve survival in elderly patients with FLT3-ITD AML, suggesting a need for alternative strategies.

Key Points

  • Maintenance therapy did not improve survival outcomes among elderly patients aged 60 and older with FLT3-ITD AML.
  • Overall survival and relapse-free survival rates at 48 months were similar between gilteritinib and placebo groups.
  • Observational analysis of patients with FLT3-ITD AML undergoing allogeneic HCT showed increased non-relapse mortality with gilteritinib.
  • Approaches to reduce toxicity are necessary to enhance the benefits of maintenance therapy in older adults.

Cite This Study

Abedin et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfbehttps://doi.org/10.1182/blood-2025-170
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  2. 2Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  3. 3Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib2025
  4. 4Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  5. 5Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study2025